| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10814002 | HISAMITSU | Patch and method for producing the same |
Jul, 2033
(9 years from now) | |
| US10583121 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US11123305 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US9687474 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US10022445 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US11813364 | HISAMITSU | Patch |
Sep, 2033
(9 years from now) | |
Secuado is owned by Hisamitsu.
Secuado contains Asenapine.
Secuado has a total of 6 drug patents out of which 0 drug patents have expired.
Secuado was authorised for market use on 11 October, 2019.
Secuado is available in system;transdermal dosage forms.
Secuado can be used as method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch.
The generics of Secuado are possible to be released after 22 September, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2022 |
Drugs and Companies using ASENAPINE ingredient
Market Authorisation Date: 11 October, 2019
Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch
Dosage: SYSTEM;TRANSDERMAL
SECUADO family patents
